NIH Reporter #5R21AI169111-02

NIH Solicitation for Construction of a Novel c-di-AMP-based Recombinant BCG Vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is seeking proposals for the development of a novel c-di-AMP-based recombinant BCG vaccine to enhance tuberculosis protection. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Products/Services Requested: - Construction of a novel c-di-AMP-based recombinant BCG vaccine - Includes development of c-di-AMP secreting BCG strains - Evaluation of immunogenicity and protection in animal models - Lump sum procurement for the entire vaccine construction and evaluation process - Unique or Notable Requirements: - Focus on improving efficacy against tuberculosis by engineering BCG strains to secrete c-di-AMP - Evaluation of vaccine performance in animal models is required - Open to all qualified applicants; no brand or manufacturer restrictions - Classification: - Microbiology and Infectious Diseases - Water and Sewer Line and Related Structures Construction codes (for administrative classification)

Description

This project aims to develop a recombinant BCG vaccine secreting c-di-AMP to improve efficacy against tuberculosis. The scope includes constructing c-di-AMP secreting strains and evaluating their immunogenicity and protection in animal models. The procurement involves the construction of the recombinant BCG vaccine as a lump sum item. The project is open for applications with a response due date of February 1, 2024.

View original listing